{"page":{"totalFilteredElements":40},"studies":[{"active":true,"description":"A Phase IIIb, randomized, multicenter, open-label trial of&#160;Atezolizumab plus Bevacizumab<br />versus transarterial Chemoembolization (TACE)&#160;in intermediate-stage HepatoCellular Carcinoma","eudractNumber":"2020-004210-35","id":6680,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":"NCT04803994","phase":{"id":"ph_10","name":"Phase IIIB"},"recruitmentStart":"2022-04-05T10:12:06+02:00","shortTitle":"ABC-HCC","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Beobachtungsstudie und Biobank f&#252;r Rezidive einer akuten lymphoblastischen Leuk&#228;mie im Kindes- und Jugendalter<br />","eudractNumber":null,"id":656,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2012-10-01T09:06:33+02:00","shortTitle":"ALL- REZ BFM","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"<div>A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator&#8217;s Choice in Participants with Chemotherapy-na&#239;ve Metastatic Castration-resistant Prostate Cancer</div>","eudractNumber":"2025-520555-89","id":11331,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":"NCT07213674","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-15T10:26:05+01:00","shortTitle":"AMG 509 20230239","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter \nStudy of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell \nLung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent \nChemoradiation Therapy","eudractNumber":"2023-506235-15","id":9281,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"}],"mutations":[],"nctNumber":"NCT06117774","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-12-13T10:24:08+01:00","shortTitle":"AMG 757 20230016 (DeLLphi-306)","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)","eudractNumber":"2024-511838-12-00","id":9817,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"}],"mutations":[],"nctNumber":"NCT06598306","phase":{"id":"ph_14","name":"Phase I/IB"},"recruitmentStart":"2024-11-26T10:56:41+01:00","shortTitle":"AMG 757 20230298 (DeLLphi-308)","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 3, Open-label, Multicenter, Randomized&#160;Study of Xaluritamig vs Cabazitaxel or Second&#160;Androgen Receptor-Directed Therapy in&#160;Subjects With Metastatic Castration-Resistant&#160;Prostate Cancer Previously Treated With&#160;Chemotherapy","eudractNumber":"2024-513968-25","id":10039,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-25T09:31:19+02:00","shortTitle":"AMG509 20230005 STEAP-1","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123&#160;Consisting of Genetically Modified T cells Carrying Reverse Chimeric&#160;Antigen Receptors (Allo-RevCAR01-T) in Combination With CD123&#160;Target Module (R-TM123) for the Treatment of Patients With Selected&#160;Hematologic Malignancies Positive for CD123","eudractNumber":"2022-501797-19","id":8333,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD123 ","id":"mt_79"}],"nctNumber":"NCT05949125","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2024-02-20T12:54:04+01:00","shortTitle":"AVC-201-01","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 2/3 Open Label Randomized Study of\nTelisotuzumab Adizutecan Compared to Standard of Care in Subjects with Locally\nAdvanced or Metastatic EGFR-Mutated Non-Squamous Non- Small Cell Lung Cancer\nAfter Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713","eudractNumber":"2025-521124-29-00","id":11332,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"EGFR","id":"mt_1"}],"nctNumber":"NCT07155187","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2026-03-02T10:56:01+01:00","shortTitle":"Abbvie M25-713 AndroMETa-Lung-713","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Allogene Stammzelltransplantation im Vergleich zur konventionellen \nTherapie als Salvage-Therapie f&#252;r Patienten mit rezidiviertem / \nprogredientem multiplen Myelom nach einer Erstlinientherapie\n(AlloRelapseMMStudy)","eudractNumber":"2021-001005-67","id":8119,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05675319","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-04-05T10:24:45+02:00","shortTitle":"AlloRelapseMMStudy - CTC201637","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone and Carfilzomib/ Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma and t(11; 14)","eudractNumber":"2021-003614-39","id":9079,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"Translokation","id":"mt_244"},{"name":"t(11;14)","id":"mt_78"}],"nctNumber":"NCT04973605","phase":{"id":"ph_15","name":"Phase IB/II"},"recruitmentStart":"2025-05-07T12:24:50+02:00","shortTitle":"BGB-11417-105","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]}]}